News Archive

The rate of transmission within schools was found to be much lower than the rate of community spread of the disease.

Perakslis will provide strategic vision and oversight of DCRI’s digital research initiatives and technology affairs to advance the academic institute’s clinical research portfolio.

The Duke Clinical Research Institute (DCRI) and Verily are utilizing the HERO Registry and community to launch a study to gain long-term insights about the COVID-19 vaccine developed by Pfizer and BioNTech, including real-world safety data. This study, which is funded by Pfizer, will follow vaccinated healthcare workers for two years to assess their experiences after receiving the vaccine.

Data from electronic health record (EHR) systems—including on prescribing patterns—are often not available to clinicians in an aggregated or easily digestible format.

DCRI population health scientists conducted a discrete choice experiment to improve understanding of how people weigh risks associated with COVID-19. A partisan split in reaction to COVID-19 has been widely publicized in the media—but new research from DCRI population health scientists suggests that it may not be that simple.

The annual list, which examined papers published over the last decade, honors researchers who were in the top 1 percent of citations in their fields.

Two presentations on the American Heart Association COVID Registry shared data about COVID-19 hospitalizations collected from over 100 hospitals.

Through new ways of working and collaborations across Duke, the DCRI’s Clinical Events Classification group is continuously improving on its processes.

The study, which is the only randomized trial testing rixaroxaban in this patient population, builds on previous evidence established by the DCRI-led ROCKET-AF and ARISTOTLE studies.

Patients assigned to the treatment, omecamtiv mecarbil, experienced a statistically significant difference in a composite endpoint of time to cardiovascular death or time to first heart failure event.